In a report released today, William Tanner from Cantor Fitzgerald reiterated a Buy rating on Optinose Inc (NASDAQ: OPTN), with a price target of $30. The company’s shares opened today at $19.92.
Tanner said:
“: We reiterate the OW rating and $30 PT for OPTN stock. We believe Xhance could significantly change the manner in which nasal polyps (NP) are treated and successful development in the chronic sinusitis (CS) indication. Over the nearer term, we suspect investors will primarily focus on launch metrics as is typical for practically any new product. OPTN shares are trading -25% intraday.”
According to TipRanks.com, Tanner is a 3-star analyst with an average return of 2.0% and a 44.5% success rate. Tanner covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Supernus Pharmaceuticals, and Aquinox Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Optinose Inc with a $31.33 average price target.
See today’s analyst top recommended stocks >>
Based on Optinose Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $30.57 million. In comparison, last year the company had a GAAP net loss of $8.75 million.
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OptiNose, Inc. is a pharmaceutical company, which engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in May 2010 and is headquartered in Yardley, PA.
